Supported by the positive outcomes of combinational therapies involving MDM2 inhibitors, therapies targeting E3s upstream of PTEN may offer synergistic benefits in overcoming drug resistance and improving treatment outcomes in cancers with reduced PTEN expression. The gene discussed is PTEN; the disease is cancer.